Celsion Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Celsion stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLSN, but not buy additional shares or sell existing shares.
View analyst ratings for Celsion or view top-rated stocks.

Wall Street analysts have given Celsion a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Celsion wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Celsion is scheduled to release its next quarterly earnings announcement on Friday, August 13th 2021.
View our earnings forecast for Celsion.

Celsion Co. (NASDAQ:CLSN) posted its quarterly earnings data on Friday, May, 14th. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.06) by $0.03. Celsion had a negative trailing twelve-month return on equity of 67.84% and a negative net margin of 4,423.40%.
View Celsion's earnings history.

Celsion's stock was trading at $0.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CLSN shares have increased by 25.3% and is now trading at $1.24.
View which stocks have been most impacted by COVID-19.

Celsion shares reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

2 brokerages have issued 1 year price objectives for Celsion's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Celsion's share price to reach $4.00 in the next year. This suggests a possible upside of 222.6% from the stock's current price.
View analysts' price targets for Celsion or view top-rated stocks among Wall Street analysts.

Some companies that are related to Celsion include Amryt Pharma (AMYT), Oramed Pharmaceuticals (ORMP), Kindred Biosciences (KIN), VistaGen Therapeutics (VTGN), ANI Pharmaceuticals (ANIP), Angion Biomedica (ANGN), Tonix Pharmaceuticals (TNXP), Verona Pharma (VRNA), Werewolf Therapeutics (HOWL), Puma Biotechnology (PBYI), KemPharm (KMPH), Cue Biopharma (CUE), Terns Pharmaceuticals (TERN), Homology Medicines (FIXX) and DURECT (DRRX).
View all of CLSN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Novan (NOVN), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), Agenus (AGEN) and CBL & Associates Properties (CBL).

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Celsion's stock is owned by a variety of retail and institutional investors. Top institutional investors include Altium Capital Management LP (4.04%), Morgan Stanley (2.24%), BlackRock Inc. (1.31%), Geode Capital Management LLC (0.59%), Eudaimonia Partners LLC (0.17%) and Northern Trust Corp (0.14%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Donald P Braun, Frederick J Fritz and Jeffrey Wayne Church.
View institutional ownership trends for Celsion.

CLSN stock was sold by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC.
View insider buying and selling activity for Celsion or view top insider-selling stocks.

CLSN stock was acquired by a variety of institutional investors in the last quarter, including Altium Capital Management LP, Morgan Stanley, BlackRock Inc., Geode Capital Management LLC, Virtu Financial LLC, XTX Topco Ltd, Northern Trust Corp, and HRT Financial LP. Company insiders that have bought Celsion stock in the last two years include Alberto R Martinez Jr, Donald P Braun, Frederick J Fritz, and Jeffrey Wayne Church.
View insider buying and selling activity for Celsion or or view top insider-buying stocks.

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CLSN stock can currently be purchased for approximately $1.24.

Celsion has a market capitalization of $107.33 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-21,480,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

Celsion employs 27 workers across the globe.

The official website for Celsion is www.celsion.com.

Celsion is headquartered at 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648.

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at (609) 896-9100 or via email at [email protected]